AMMAX BIO, INC.

AmMax Bio Doses First Patient in Phase 2a Trial of AMB-066 for Colorectal Cancer MRD

5 months ago

• AmMax Bio has dosed the first patient in a Phase 2a study evaluating AMB-066 for colorectal cancer minimal residual disease (CRC MRD). • The trial, led by Dr. Van K. Morris at MD Anderson Cancer Center, aims to address the unmet need for approved therapies for CRC MRD. • AMB-066, a monoclonal antibody targeting CSF1R, has shown promise in preclinical data and a safety database of approximately 200 individuals. • Approximately 20,000 patients are diagnosed annually in the U.S. with CRC MRD, which currently has no approved therapies beyond observation.

Advancements in Tenosynovial Giant Cell Tumors Clinical Trials Highlighted for 2024

6 months ago

The Tenosynovial Giant Cell Tumors (TGCT) clinical trials landscape for 2024 showcases significant progress, with over 5 key companies developing more than 5 treatment therapies. Notable developments include the FDA's priority review for vimseltinib, a CSF1R inhibitor, and the EMA's acceptance of its Marketing Authorization Application, signaling a promising future for TGCT treatment.

Tenosynovial Giant Cell Tumors Treatment Market to See Significant Growth by 2034

10 months ago

The Tenosynovial Giant Cell Tumors (TSGCTs) treatment market, valued at approximately USD 300 million in 2023, is expected to grow significantly by 2034. This growth is driven by the increasing prevalence of TSGCTs, advancements in treatment options, and the introduction of novel therapies. Key developments include SynOx Therapeutics securing USD 75 million in Series B funding for the development of emactuzumab, a promising treatment for TSGCTs.